



## Liver Regeneration and Its Emerging Applications in Cell Therapy and Tissue Engineering: A Comprehensive Review

Dr Benashvili Levan

Department of Clinical Anatomy and Operative Surgery, Tbilisi State Medical University, Vaja Pshavela ave.33, Tbilisi, Georgia

### Corresponding Author

#### Dr Benashvili Levan

Department of Clinical Anatomy and Operative Surgery, Tbilisi State Medical University, Vaja Pshavela ave.33, Tbilisi, Georgia

Source of support: Nil.

Conflict of interest: None

Received: 03-11-2025

Accepted: 04-12-2025

Available online: 24-12-2025



This work is licensed under the Creative Commons Attribution 4.0 License.

Published by TRJMS

### Abstract

Liver regeneration is an extraordinary biological phenomenon characterized by the organ's ability to restore its mass and function after injury, surgical resection, or disease. This process is predominantly driven by the proliferation of mature hepatocytes, regulated by intricate cellular and molecular signaling pathways, and influenced by the local microenvironment, immune response, and systemic factors (1–6). Despite extensive research, many aspects of liver regenerative biology remain to be elucidated, particularly regarding the limited role of resident stem/progenitor cells and the potential contribution of circulating progenitors (7–10). Recent advancements in molecular biology, stem cell technology, biomaterials, and biofabrication are paving the way for innovative approaches such as cell therapy, tissue engineering, and bioprinting to treat liver failure (11–12). Future prospects include the development of vascularized bioengineered organs, gene editing techniques, and personalized regenerative strategies, which may revolutionize the management of liver diseases. Nevertheless, significant scientific, technical, regulatory, and ethical challenges must be overcome before these therapies become clinical reality. This review highlights current understanding of liver regenerative mechanisms, examines emerging therapeutic approaches, and explores future directions in liver tissue engineering and regenerative medicine.

**Keywords:** Liver Regeneration, Emerging, Cell Therapy, Tissue.

### INTRODUCTION

Liver regeneration is a remarkable and complex biological process fundamental to maintaining liver function after injury or damage (1,2,4). Despite decades of study, many aspects of this process remain elusive due to its dependence on etiological factors, the extent of injury, and the genetic background of the individual. Understanding the cellular and molecular mechanisms that orchestrate liver regeneration is essential for advancing regenerative strategies—including cell therapy and tissue engineering—intended to treat acute and chronic liver diseases. Recent technological innovations have expanded the therapeutic landscape, making the prospect of engineered liver tissues or even whole-organ replacements increasingly feasible (5,6).

### The Complexity of Liver Regeneration

The liver's regenerative capacity is one of the most remarkable phenomena in human physiology (1,3,4). Unlike most organs, which rely heavily on resident stem cell populations, the liver primarily restores structure and function through the proliferative response of mature hepatocytes. This response is triggered by diverse forms of injury, including surgical resection (partial hepatectomy) (16), toxin exposure, ischemia, or chronic inflammation. The regenerative response is highly orchestrated, involving a cascade of cytokine and growth factor signaling pathways—including TNF- $\alpha$ , IL-6,

HGF, and EGF—that coordinate hepatocyte proliferation, differentiation, and tissue remodeling (4,18,19).

Mature hepatocytes exit quiescence (G0), re-enter the cell cycle, and proliferate rapidly—often restoring liver mass within days. This rapid regrowth is essential to maintain vital metabolic, synthetic, and detoxification functions. Regenerative efficiency varies by context: acute injuries elicit robust hepatocyte-driven regeneration, whereas chronic injury leads to dysregulated repair, excessive extracellular matrix deposition, and progressive fibrosis, which can culminate in cirrhosis and hepatic failure (2,5). Vascular remodeling, immune activation, and metabolic shifts are also critical determinants of regenerative outcomes (23).

### **Cellular and Molecular Mechanisms of Regeneration**

The central drivers of liver regeneration are mature hepatocytes, which constitute roughly 80% of liver mass (1,3,6). Following injury, hepatocyte proliferation is initiated by cytokine-mediated priming, primarily TNF- $\alpha$  and IL-6, which enable cells to respond to mitogens (4,19). Subsequent stimulation by HGF, EGF, TGF- $\alpha$ , and Wnt/ $\beta$ -catenin signaling induces DNA synthesis and cell division (4,8,24,25). Extracellular matrix remodeling, angiogenesis, and immune cell recruitment ensure appropriate tissue integration and vascular supply (23).

Resident progenitor cells, often referred to as oval cells, may contribute under circumstances where hepatocyte proliferation is impaired, such as severe chronic injury (7,9,22). These cells can differentiate into hepatocytes or biliary cells but typically play a secondary role under normal conditions. Bone marrow-derived circulating progenitors can also differentiate into hepatocyte-like cells, though their contribution rarely exceeds 1–2% of the new hepatocyte population (10,28).

Advances in molecular biology have uncovered regulatory networks controlling proliferation, differentiation, immune interactions, and extracellular matrix dynamics, forming the basis for designing targeted regenerative therapies capable of restoring liver function or preventing maladaptive repair (6,24).

### **Future Directions in Liver Regeneration and Tissue Engineering**

#### **Enhanced Stem Cell Therapies**

Pluripotent stem cell (PSC)-based therapies provide a renewable source of patient-specific hepatocytes, presenting a transformative solution for liver failure (5,7,15). However, PSC-derived hepatocyte-like cells often exhibit incomplete maturation and limited *in vivo* engraftment. Strategies to optimize PSC differentiation include harnessing developmental signaling pathways, incorporating biomimetic 3D scaffolds to promote polarization and metabolic maturation, and applying genetic enhancement to improve survival and integration. Integration of biochemical cues, biophysical stimuli, and gene editing may overcome barriers to functional, scalable hepatocyte production for translational use (6,7,15).

#### **3D Bioprinting and Organoid Technologies**

3D bioprinting and organoid-based systems offer platforms to construct complex liver tissues that recapitulate native architecture (10–12,26,27). High-resolution bioprinting enables deposition of hepatocytes, endothelial cells, and stromal populations into controlled, multi-material structures. Microfluidic-assisted printing allows formation of perfusable vascular channels that support long-term viability. Organoids derived from PSCs provide self-organizing building blocks that enhance tissue complexity, bile canaliculi formation, and metabolic activity, generating patient-specific constructs suitable for transplantation, disease modeling, and drug testing.

#### **Vascularization and Integration**

Functional vascular networks are essential for oxygenation, nutrient exchange, and metabolic activity in engineered constructs (11,23,27). Replicating the liver's dense sinusoidal architecture remains a major challenge. Advances include microfluidic systems for patterning vascular channels and regulating shear stress, biomaterials functionalized with pro-angiogenic factors to enhance host vessel infiltration, and 3D bioprinting strategies that spatially organize endothelial and stromal cells for rapid inosculation. Computational modeling and endothelial progenitor engineering are expected to further improve perfusable, transplantable tissues.

#### **Gene Editing and Personalized Medicine**

CRISPR/Cas9, base editing, and prime editing technologies enable precise correction of genetic defects and enhancement of hepatocyte function (6,7). Gene editing allows generation of autologous, mutation-corrected hepatocytes, optimization of metabolic pathways, and creation of universal donor cells through HLA modification. Coupled with PSC-derived organoids and patient-specific iPSC models, these approaches facilitate precision therapies tailored to individual genetic backgrounds. Challenges include genomic stability, off-target effects, regulatory compliance, and ethical considerations. Nonetheless, gene-edited liver tissues may become clinically routine within decades (6,15).

## CONCLUSION

Liver regeneration represents a unique and powerful biological process, primarily driven by the proliferative capacity of mature hepatocytes coordinated through intricate networks of cytokines, growth factors, and signaling pathways (1–4,19). Under physiological conditions and acute injury, this process is remarkably efficient, enabling rapid restoration of liver mass and essential liver functions, including metabolism, detoxification, and protein synthesis (16,18). However, in chronic liver diseases such as cirrhosis, steatohepatitis, or prolonged toxin exposure, the regenerative response becomes dysregulated, leading to fibrotic remodeling, impaired parenchymal restoration, and ultimately, organ failure (2,5). Understanding these mechanisms at the cellular and molecular levels—including the roles of resident stem/progenitor cells, bone marrow-derived progenitors, and the liver microenvironment—is fundamental for developing strategies to enhance or restore regenerative capacity (7–10,23).

Recent advances in regenerative medicine and tissue engineering are poised to transform the landscape of liver therapy. Stem cell–derived hepatocytes, pluripotent stem cell technologies, and organoid systems provide renewable sources of functional liver cells, while advanced biomaterials, decellularized scaffolds, and 3D bioprinting enable the reconstruction of tissue architecture, vascular networks, and organ-level complexity (10–12,26,27). Gene editing technologies, including CRISPR/Cas9, base editing, and prime editing, allow precise correction of genetic defects, metabolic pathway optimization, and the generation of patient-specific or universal donor hepatocytes (6,15). These combined approaches hold the potential to alleviate the global shortage of donor organs, reduce dependence on transplantation, and provide innovative therapies for both acute and chronic liver diseases.

Despite these promising advances, significant challenges remain. Replicating the liver's intricate architecture, establishing stable and perfusable vascular networks, supporting bile duct formation, ensuring long-term cell viability, and preventing immune rejection are formidable obstacles (11,23,27). Translating these technologies into clinical practice will also require rigorous preclinical safety validation, reproducible manufacturing protocols, and careful consideration of ethical, regulatory, and socioeconomic factors (13–15).

Looking forward, continued interdisciplinary research integrating developmental biology, stem cell biology, bioengineering, materials science, immunology, and clinical hepatology is critical. The convergence of these fields is expected to enable the generation of fully functional, vascularized, and patient-specific liver constructs suitable for transplantation, disease modeling, and drug testing (10–12,27). With sustained scientific and technological progress, engineered liver tissues or even entire bioengineered organs may emerge as transformative, life-saving treatments, ultimately revolutionizing the management of liver disease and improving outcomes for patients worldwide (5,11,12).

## REFERENCES

1. Michalopoulos, G. K., & DeFrances, M. C. (1997). Liver regeneration. *Science*, 276(5309), 60–66.
2. Fausto, N. (2000). Liver regeneration. *Journal of Hepatology*, 32(1 Suppl), 19–31.
3. Michalopoulos, G. K. (2007). Liver regeneration. *Journal of Cellular Physiology*, 213(2), 286–300.
4. Taub, R. (2004). Liver regeneration: From myth to mechanism. *Nature Reviews Molecular Cell Biology*, 5(10), 836–847.
5. Forbes, S. J., & Newsome, P. N. (2016). Liver regeneration — mechanisms and models to clinical application. *Nature Reviews Gastroenterology & Hepatology*, 13(8), 473–485.
6. Michalopoulos, G. K. (2017). Liver Regeneration: Molecular Mechanisms of Growth Control. *Methods in Molecular Biology*, 1595, 1–19.
7. Duncan, A. W., Dorrell, C., & Grompe, M. (2009). Stem cells and liver regeneration. *Gastroenterology*, 137(2), 466–481.
8. Fausto, N., Campbell, J. S., & Riehle, K. J. (2006). Liver regeneration. *Hepatology*, 43(S1), S45–S53.
9. Huch, M., & Clevers, H. (2011). Sox9+ liver progenitors and liver regeneration. *Nature*, 475(7355), 453–456.
10. Huch, M. et al. (2013). Long-term expansion of functional mouse and human hepatocytes as 3D organoids. *Nature*, 494, 247–250.
11. Baptista, P. M. et al. (2011). The use of whole organ decellularization for the generation of a vascularized liver organoid. *Hepatology*, 53(2), 604–617.
12. Soto-Gutiérrez, A., Wertheim, J. A., Ott, H. C., & Gilbert, T. W. (2019). Perspectives on whole-organ bioengineering. *Cell Stem Cell*, 25(1), 16–24.
13. Fox, I. J., & Roy-Chowdhury, J. (2004). Hepatocyte transplantation. *Journal of Hepatology*, 40(6), 878–886.
14. Sokal, E. M., & Smets, F. (2010). Hepatocyte transplantation: Where do we stand? *Journal of Pediatric Gastroenterology and Nutrition*, 50(2), 222–227.
15. Huebert, R. C., & Rakela, J. (2014). Cellular therapy for liver disease: From liver transplantation to cell-based therapy. *Transplantation Reviews*, 28(1), 1–8.
16. Higgins, G. M., & Anderson, R. M. (1931). Experimental pathology of the liver. I. Restoration of the liver of the white rat following partial surgical removal. *Archives of Pathology*, 12, 186–202.

17. Michalopoulos, G. K. (1990). Liver regeneration: Molecular mechanisms of growth control. *FASEB Journal*, 4(13), 176–187.
18. Nakamura, T., Nawa, K., & Ichihara, A. (1984). Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. *Biochemical and Biophysical Research Communications*, 122(3), 1450–1459.
19. Cressman, D. E., Greenbaum, L. E., DeAngelis, R. A., Ciliberto, G., Furth, E. E., Poli, V., & Taub, R. (1996). Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. *Science*, 274(5291), 1379–1383.
20. Taub, R. (2004). Liver regeneration: From myth to mechanism. *Nature Reviews Molecular Cell Biology*, 5(10), 836–847.
21. Fausto, N. (2000). Liver regeneration. *Journal of Hepatology*, 32(1 Suppl), 19–
22. Duncan, A. W., Dorrell, C., & Grompe, M. (2009). Stem cells and liver regeneration. *Gastroenterology*, 137(2), 466–481.
23. Ding, B.-S., Nolan, D. J., Butler, J. M., James, D., Babazadeh, A. O., Rosenwaks, Z., ... & Rafii, S. (2010). Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. *Nature*, 468(7321), 310–315.
24. Zhao, B., Li, L., Lei, Q., & Guan, K.-L. (2010). The Hippo–YAP pathway in organ size control and tumorigenesis. *Genes & Development*, 24(9), 862–874.
25. Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S. A., ... & Guan, K.-L. (2007). Elucidation of a universal size-control mechanism in *Drosophila* and mammals: YAP activation causes liver overgrowth. *Cell*, 130(6), 1120–1133.
26. Huch, M., Dorrell, C., Boj, S. F., van Es, J. H., Li, V. S., van de Wetering, M., ... & Clevers, H. (2013). In vitro expansion of single Lgr5<sup>+</sup> liver stem cells induced by Wnt-driven regeneration. *Nature*, 494, 247–250.
27. Baptista, P. M., Siddiqui, M. M., Lozier, G., Rodriguez, S., Atala, A., Soker, S., ... & Farney, A. (2011). The use of whole organ decellularization for the generation of a vascularized liver organoid. *Hepatology*, 53(2), 604–617.
28. Fox, I. J., Chowdhury, J., Kaufman, S. S., Goertzen, T., Chowdhury, N., Warkentin, P., ... & Strom, S. (1998). Treatment of the Gunn rat with hepatocyte transplantation. *Seminars in Liver Disease*, 18(1), 75–83.